Measurable Residual Disease

Patients with chronic lymphocytic leukemia who achieved undetectable minimal residual disease achieved significantly longer PFS than patients with minimal residual disease, according to results of a systematic review and meta-analysis.

NEW ORLEANS — In this video perspective, Richard M. Stone, MD, discusses research presented at ASH Annual Meeting and Exhibition looking at the use of measurable residual disease to guide treatment of patients with acute myeloid leukemia.

In this video, Lori Muffly, MD, MS, spoke with Healio about her presentation on the use of measurable residual disease in treating acute lymphoblastic leukemia from the Society of Hematologic Oncology Annual Meeting.

In this video, Alexander Edward Perl, MD, MS, spoke with Healio about a study assessing the potential benefit of ceasing venetoclax-based therapy after remission in patients with acute myeloid leukemia.

In this video, Farhad Ravandi, MD, spoke with Healio about the importance of measurable residual disease assessment in AML, which was discussed at the Society of Hematologic Oncology Annual Meeting.

Myeloablative conditioning prior to allogeneic hematopoietic stem cell transplantation may result in improved survival compared with reduced-intensity conditioning for patients with acute myeloid leukemia with genomic evidence of measurable residual disease, according to results of a randomized phase 3 study published in Journal of Clinical Oncology.

ORLANDO — Blinatumomab demonstrated superiority over chemotherapy as post-reinduction consolidation prior to hematopoietic stem cell transplantation among children and young adults with B-acute lymphoblastic leukemia in intermediate- or high-risk first relapse, according to results of the Children’s Oncology Group Study AALL1331 presented during the late-breaking abstract session of ASH Annual Meeting and Exposition.